Replimune Group, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended September 30, 2018. For the quarter, the company reported a net loss of $6,461,000 compared with $4,660,000 for same period in the prior year. The increase in net loss for the year was due to increased research and development expenses as well as expenses related to Replimune's initial public offering (IPO). Net loss per share attributable to common stockholders, basic and diluted was $0.26 compared to $0.94 a year ago. Loss from operations of $7,104,000 compared with $4,256,000 for same period in the prior year.

For the six months, the company reported net loss of $16,505,000 compared with $8,212,000 for same period in the prior year. Net loss per share attributable to common stockholders, basic and diluted was $1.11 compared to $1.65 a year ago. Loss from operations of $12,983,000 compared with $7,432,000 for same period in the prior year.

For the second half of 2021, Based on its current operating plan, the company expects that its current cash, cash equivalents and short-term investments will enable it to fund its operating expenses and capital expenditure requirements into the second half of 2021.